TNDM · XBRL financial data

Tandem Diabetes Care financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TNDM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	499	703	801	748	940	1,015
Cost of goods and services sold	238	327	388	380	451	469
Gross profit	261	376	413	368	490	546
Research and development	64	92	—	—	—	—
Selling, general and administrative	205	262	336	353	390	445
Total operating expenses	268	354	506	601	589	733
Operating income (loss)	(8)	23	(93)	(233)	(99)	(187)
Interest expense	—	—	6	10	7	8
Other income (expense)	(28)	(7)	(0)	13	7	(13)
Income tax expense (benefit)	(2)	0	2	2	4	4
Net income (loss)	(34)	16	(95)	(223)	(96)	(205)
Earnings per share, basic USD per share	(0.56)	0.25	(1.47)	(3.43)	(1.47)	(3.04)
Earnings per share, diluted USD per share	(0.56)	0.24	(1.47)	(3.43)	(1.47)	(3.04)
Weighted average shares, basic millions of shares	61	63	64	65	65	67
Weighted average shares, diluted millions of shares	61	64	64	65	65	67

Fiscal years (TNDM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	95	71	173	59	69	91
Short-term investments	390	553	444	409	369	202
Accounts receivable	82	111	115	106	115	165
Inventory	64	69	111	158	150	129
Prepaid and other current assets	6	8	7	17	22	31
Total current assets	637	812	850	748	724	618
Property and equipment, net	50	50	69	77	78	84
Right-of-use asset	20	28	111	88	85	96
Total assets	716	905	1,053	953	968	881
Accounts payable	18	28	56	50	45	47
Accrued liabilities	5	9	10	13	18	21
Current portion of long-term debt	—	—	—	0	41	—
Total current liabilities	104	132	165	195	247	243
Long-term debt	—	—	—	285	308	310
Lease liability, non-current	16	24	124	114	106	115
Total liabilities	350	472	613	639	705	726
Accumulated deficit	(659)	(635)	(729)	(952)	(1,048)	(1,253)
Total stockholders' equity	366	433	440	314	263	155
Total liabilities and equity	716	905	1,053	953	968	881
Common shares outstanding (cover page) millions of shares	63	64	65	66	66	68

Fiscal years (TNDM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(34)	16	(95)	(223)	(96)	(205)
Stock-based compensation	58	61	85	88	101	92
Depreciation and amortization	10	14	14	16	17	18
Net cash from operating activities	25	111	50	(32)	24	(10)
Purchases of property and equipment	27	14	34	27	19	20
Net cash from investing activities	(296)	(187)	33	(86)	(23)	73
Proceeds from issuing common stock	67	51	17	4	(7)	—
Share repurchases	—	—	0	0	30	0
Net cash from financing activities	314	52	17	4	8	(43)
Net change in cash	43	(23)	101	(114)	10	21

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Tandem Diabetes Care	63	255	(35)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Artivion	77	126	(1.3)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
AtriCure	187	154	not reported	50.9M	—	Q3 FY26 10-QSep 30, 2026
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	—	Q2 FY26 10-QJun 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Ufp Technologies	9	174	16*	7.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.